Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Revenue from contract with customers (Details)

v3.10.0.1
Summary of Significant Accounting Policies - Revenue from contract with customers (Details)
 1 Months Ended 3 Months Ended 6 Months Ended 50 Months Ended
Sep. 30, 2017
USD ($)
Jun. 30, 2014
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
contract
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
Collaboration and License Agreement              
Option exercise fee     $ 9,038,000 $ 3,521,000 $ 17,234,000 $ 6,378,000  
GlaxoSmithKline Intellectual Property Development Ltd | Collaboration and License Agreement              
Collaboration and License Agreement              
Number of contracts with customers | contract         1    
Upfront payment received   $ 42,123,000          
Amount of development milestone achieved             $ 53,691,000
Estimate of variable consideration         $ 25,544,000    
License exercise fee, expected to be received         $ 13,198,000    
Licenses | GlaxoSmithKline Intellectual Property Development Ltd | Collaboration and License Agreement              
Collaboration and License Agreement              
Option exercise fee $ 26,610,000